Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dental pulp mesenchymal stem cells for idiopathic pulmonary fibrosis
IRCT20140911019125N15Phase 2Recruiting
- Sponsor
- Kerman University of Medical Sciences
- Start
- May 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of dental pulp mesenchymal stem cells in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Lung diffusing capacity, Total lung volume and 3 more. Started May 2025; status: recruiting.
02
Drugs
dental pulp mesenchymal stem cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on IRCT20140911019125N15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140911019125N15.